Laboratory management software can’t build a perfectly optimized construct for an in vivo CAR-T cell therapy, but it can make the lives of the scientists doing so considerably easier.
When you combine an ethical, plentiful human tissue source with disciplined manufacturing and true codevelopment partnerships, you get a realistic way to scale human-derived biomaterials.
The real risk is not that one country pulls ahead. It’s that friction — political, regulatory or economic — slows the system as a whole.
The American Society for Clinical Oncology annual meeting never fails to deliver inspiring advances in cancer-care.
In theory, in vivo makes other cell therapies obsolete, but a panel at BPI Europe in Vienna last month painted a more measured picture.
Here are 10 best practices that can help drug developers avoid delays, protect data quality, and meet regulatory, clinical and manufacturing expectations.
Developers who treat China’s rise as a strategic opportunity — both for partnership and as a wakeup call to address inefficiencies in Western systems — will be best positioned to take home the ultimate prize: bringing lifesaving treatments to more patients.
Robust CCI verification is essential not only for regulatory compliance but also for protecting product stability and patient safety. As advanced therapies become more complex, the rigor and precision of CCI testing will remain indispensable.
Wednesday, April 29, 2026
The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication.
Wednesday, April 15, 2026
Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients.
Wednesday, April 01, 2026